Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 7;12(9):2541. doi: 10.3390/cancers12092541

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Synergistic effect of GSK126 and pomalidomide is dependent on cereblon (CRBN), but not degradation of IKAROS family zinc finger 1 (IKZF1) or 3 (IKZF3). (A) CRBN levels were examined via western blot in shControl and shCRBN WSU-DLCL2 cells. (B) Effects of pomalidomide and GSK126 on the viability of shControl and shCRBN WSU-DLCL2. Cells were treated with the indicated concentrations of GSK126 and pomalidomide (Pom) for 6 days. (C) Combination index (CI) values obtained for shControl and shCRBN WSU-DLCL2. Cells were treated with different concentrations of pomalidomide in combination with GSK126 (1 μM). (D) Western blot analysis of IKZF3 and IKZF1 levels in shControl, shIKZF1, and shIKZF3 WSU-DLCL2. (E) Effects of pomalidomide and GSK126 on the viability of shControl, shIKZF1, and shIKZF3 WSU-DLCL2. Cells were treated with the indicated concentrations of GSK126 and pomalidomide (Pom) for 6 days. (F) Combination index (CI) values obtained for shControl, shIKZF1, and shIKZF3 WSU-DLCL2. Cells were treated with different concentrations of pomalidomide in combination with GSK126 (1 μM). (*** p-value < 0.0001, Student’s t-test).